Ignite Creation Date:
2024-05-06 @ 4:00 PM
Last Modification Date:
2024-10-26 @ 2:01 PM
Study NCT ID:
NCT04833114
Status:
RECRUITING
Last Update Posted:
2023-10-12
First Post:
2021-02-10
Brief Title:
Polatuzumab Vedotin Plus Rituximab Ifosfamide Carboplatin and Etoposide Pola-R-ICE Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma DLBCL
Sponsor:
GWT-TUD GmbH
Organization:
GWT-TUD GmbH
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-04-30
Start Date Type:
ACTUAL
Primary Completion Date:
2024-10-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2021-02-10
First Submit QC Date:
April 2 2021
Study First Post Date:
2021-04-06
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-10-11
Last Update Post Date:
2023-10-12
Last Update Post Date Type:
ACTUAL